An overview of the current management and emerging therapies of Multiple system atrophy.
An overview of the current management and emerging therapies of Multiple system atrophy.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Salerno, IT · Author affiliation
Neurological Clinic, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.Location evidence
Bologna, IT · Author affiliation
Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
IntroductionMultiple system atrophy is a sporadic α-synucleinopathy, characterized by parkinsonism, cerebellar and pyramidal signs combined in different ways, in association with autonomic failure. In absence of disease-modifying therapies, management is directed toward symptomatic treatment and maintenance of function.Areas coveredThis review critically appraises current evidence, highlights novel therapeutic strategies, and provides guidance for clinical practice and future research directions. A literature search without date restrictions was conducted using PubMed to identify published studies relevant to this review. Motor symptom interventions are primarily levodopa-based, yielding partial and transient responses, especially in MSA-P, whereas dopaminergic agonists, MAO-B inhibitors, amantadine, and device-aided therapies provide a limited or short-lived benefit. Physiotherapy, occupational therapy, and multidisciplinary rehabilitation are integral to motor symptoms management. Non-motor symptoms management target autonomic failure (neurogenic orthostatic hypotension, urinary/sexual dysfunction, etc.), gastrointestinal dysmotility and sleep disorders (REM sleep Behavior Disorder, stridor, etc.), using a stepwise combination of lifestyle measures, pharmacological agents and device-aided interventions.Expert opinionManagement of MSA remains largely symptomatic. Multimodal treatment and integration of rehabilitative and non-pharmacological strategies are critical, while ongoing trials in neuroprotection and neuromodulation represent key avenues to improve long-term outcomes.